Photo of Olga Pozdnyakova,  MD

Olga Pozdnyakova, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-8905


opozdnyakova@bwh.harvard.edu

Olga Pozdnyakova, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Associate Professor, Pathology, Harvard Medical School
  • Associate Pathologist, Pathology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am currently a Diagnostic Hematopathologist at Brigham and Women's Hospital and Dana Farber Cancer Institute (DFCI) and an Associate Professor of Pathology at Harvard Medical School. I am the Associate Medical Director of the Clinical Hematology Laboratory at BWH and the Medical Director of the Physicians Diagnostic Laboratories at Brigham and Women’s Harbor Medical Associates (HMA) and DFCI Cancer Center and the Community Cancer Care in Weymouth.

As a member of the Hematopathology Division at BWH and a Hematopathologist, I provide comprehensive diagnostic evaluation of patients specimens, including conventional histology, as well as specialized immunological, molecular and flow cytometric tests, that result in an integrated diagnostic reports. My particular clinical expertise lies in myeloproliferative neoplasms and I am frequently consulted by my colleagues and pathologists at outside institutions. In addition, I participate in direct day-to-day instruction and education in all aspects of Hematopathology and Clinical Hematology to the fellows and residents. I also present weekly interactive clinical case conferences within the Division of Hematopathology and DFCI clinical pathologic correlation conferences. I am the course director of a bi-weekly Hematology Laboratory and Coagulation Journal Club with pathology trainees, faculty and laboratory staff. I also serve as a tutor in the Human Systems Course at Harvard Medical School. I have organized and lectured in courses at several national and international pathology conferences, including the College of American Pathologists and American Society of Clinical Pathologists. I have co-authored a textbook Hematopathology: A Volume in the High Yield Pathology Series and have authored chapters in numerous Hematology and Pathology textbooks.

My research efforts are focused on the development and application of novel approaches to diagnosing and prognostication of hematologic diseases, with specific interest in myeloid neoplasms. Using a novel gene expression platform, I analyze the contribution of the inflammatory microenvironment to the pathogenesis of myeloproliferative neoplasms. I serve as a central pathologist reviewer in several clinical trials of novel therapeutic agents for myeloproliferative neoplasm. I am also studying novel hematologic parameters on Sysmex hematology analyzers that could be used as diagnostic screening tests for cytopenic patients, potentially avoiding unnecessary and costly tests in the workup of this common clinical scenario.

Publications

Powered by Harvard Catalyst
  • Patel SS, Lipschitz M, Pinkus GS, Weirather JL, Pozdnyakova O, Mason EF, Inghirami G, Hasserjian RP, Rodig SJ, Weinberg OK. Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Mod Pathol 2020. PubMed
  • Mason EF, Hasserjian RP, Aggarwal N, Seegmiller AC, Pozdnyakova O. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv 2019; 3:3322-3332. PubMed
  • Nachmani D, Bothmer AH, Grisendi S, Mele A, Bothmer D, Lee JD, Monteleone E, Cheng K, Zhang Y, Bester AC, Guzzetti A, Mitchell CA, Mendez LM, Pozdnyakova O, Sportoletti P, Martelli MP, Vulliamy TJ, Safra M, Schwartz S, Luzzatto L, Bluteau O, Soulier J, Darnell RB, Falini B, Dokal I, Ito K, Clohessy JG, Pandolfi PP. Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. Nat Genet 2019. PubMed
  • Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, Johannessen CM, Lane AA. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest 2019. PubMed
  • Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res 2019; 29:446-459. PubMed
  • Gjini E, Jing CB, Nguyen AT, Reyon D, Gans E, Kesarsing M, Peterson J, Pozdnyakova O, Rodig SJ, Mansour MR, Joung K, Look AT. Disruption of results in myeloproliferative neoplasms in zebrafish. Dis Model Mech 2019. PubMed
  • Wong WJ, Pozdnyakova O. Myeloproliferative neoplasms: Diagnostic workup of the cythemic patient. Int J Lab Hematol 2019; 41 Suppl 1:142-150. PubMed
  • Patel S, Li Y, Berchuck JE, Cunningham J, Kim A, Pozdnyakova O. Did you "miss" me? A subtle case of intravascular large B-cell lymphoma. Am J Hematol 2018; 94:162-163. PubMed
  • Wong WJ, Baltay M, Getz A, Fuhrman K, Aster JC, Hasserjian RP, Pozdnyakova O. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS ONE 2019; 14:e0216810. PubMed
  • Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Hobbs GS, Nardi V. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol 2018. PubMed
  • Bendapudi PK, Robbins A, LeBoeuf N, Pozdnyakova O, Bhatt A, Duke F, Sells R, McQuiston J, Humrighouse B, Rouaisnel B, Colling M, Stephenson KE, Saavedra A, Losman JA. Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. Blood Adv 2018; 2:2917-2921. PubMed
  • Hergott CB, Pozdnyakova O. Evans syndrome secondary to undiagnosed chronic lymphocytic leukemia in a patient with unexplained bleeding. Am J Hematol 2018; 93:978-979. PubMed
  • Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. Association of mutations with morphological dysplasia inacute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 2018; 103:626-633. PubMed
  • Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol 2018. PubMed
  • Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS ONE 2018; 13:e0199708. PubMed
  • Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. A Distinct Immunophenotype Identifies a Subset of NPM1-mutated AML With TET2 or IDH1/2 Mutations and Improved Outcome. Am J Hematol 2017. PubMed
  • Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullaly A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histologic features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica 2017. PubMed
  • Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ. Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv 2018; 1:2269-2279. PubMed
  • Mason EF, Pozdnyakova O, Li B, Dudley G, Dorfman DM. Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders. Am J Clin Pathol 2017; 148:33-41. PubMed
  • Shanmugam V, Craig JW, Hornick JL, Morgan EA, Pinkus GS, Pozdnyakova O. Cyclin D1 is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations. Am J Surg Pathol 2017. PubMed
  • Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification. Am J Hematol 2017. PubMed
  • Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol 2016. PubMed
  • Dorfman DM, LaPlante CD, Pozdnyakova O, Li B. FLOCK cluster analysis of mast cell event clustering by high-sensitivity flow cytometry predicts systemic mastocytosis. Am J Clin Pathol 2015; 144:764-70. PubMed
  • Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med 2016; 13:294. PubMed
  • Pozdnyakova O, Laplante CD, Li B, Rosner B, Dorfman DM. High-sensitivity flow cytometric analysis of mast cell clustering in systemic mastocytosis: a quantitative and statistical analysis. Leuk Lymphoma 2015; 56:1735-41. PubMed
  • Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 2015. PubMed
  • Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol 2014. PubMed
  • Mandelker DL, Dorfman DM, Li B, Pozdnyakova O. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry. Leuk Lymphoma 2017; 55:2592-6. PubMed
Hide